Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

OBJECTIVES: Large-scale, population-based real-world studies on the treatment outcomes of first-line tyrosine kinase inhibitors (TKIs) and subsequent systemic chemotherapy agents for lung adenocarcinoma (with activating epidermal growth factor receptor [EGFR] mutations) remain limited. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Sheng-Kai, Keng, Li-Ta, Chang, Chia-Hao, Wen, Yueh-Feng, Lee, Meng-Rui, Yang, Ching-Yao, Wang, Jann-Yuan, Ko, Jen-Chung, Shih, Jin-Yuan, Yu, Chong-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821751/
https://www.ncbi.nlm.nih.gov/pubmed/33489886
http://dx.doi.org/10.3389/fonc.2020.590356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821751/
https://www.ncbi.nlm.nih.gov/pubmed/33489886
http://dx.doi.org/10.3389/fonc.2020.590356

Ejemplares similares